title: Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
authors.affiliation: Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA. Ellen_Weisberg@dfci.harvard.edu
authors.forename: Ellen
authors.initials: E
authors.lastname: Weisberg
authors.forename: Hwan Geun
authors.initials: HG
authors.lastname: Choi
authors.forename: Arghya
authors.initials: A
authors.lastname: Ray
authors.forename: Rosemary
authors.initials: R
authors.lastname: Barrett
authors.forename: Jianming
authors.initials: J
authors.lastname: Zhang
authors.forename: Taebo
authors.initials: T
authors.lastname: Sim
authors.forename: Wenjun
authors.initials: W
authors.lastname: Zhou
authors.forename: Markus
authors.initials: M
authors.lastname: Seeliger
authors.forename: Michael
authors.initials: M
authors.lastname: Cameron
authors.forename: Mohammed
authors.initials: M
authors.lastname: Azam
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Fletcher
authors.forename: Maria
authors.initials: M
authors.lastname: Debiec-Rychter
authors.forename: Mark
authors.initials: M
authors.lastname: Mayeda
authors.forename: Daisy
authors.initials: D
authors.lastname: Moreno
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Kung
authors.forename: Pasi Antero
authors.initials: PA
authors.lastname: Janne
authors.forename: Roya
authors.initials: R
authors.lastname: Khosravi-Far
authors.forename: Junia V
authors.initials: JV
authors.lastname: Melo
authors.forename: Paul W
authors.initials: PW
authors.lastname: Manley
authors.forename: Sophia
authors.initials: S
authors.lastname: Adamia
authors.forename: Catherine
authors.initials: C
authors.lastname: Wu
authors.forename: Nathanael
authors.initials: N
authors.lastname: Gray
authors.forename: James D
authors.initials: JD
authors.lastname: Griffin
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D045744:Cell Line, Tumor; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D015394:Molecular Structure; D050505:Mutant Proteins / Q000037:antagonists & inhibitors*; D020125:Mutation, Missense; D010879:Piperazines / Q000737:chemistry* / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors*; D013844:Thiazoles / Q000737:chemistry* / Q000494:pharmacology*; D013912:Threonine / Q000235:genetics; D019061:src-Family Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C552521:HG-7-85-01 compound; D050505:Mutant Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D013912:Threonine; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases